Le Lézard
Classified in: Health
Subject: POL

Stagwell (STGW) Chairman and CEO Mark Penn Releases Statement on Roe v. Wade


NEW YORK, June 24, 2022 /PRNewswire/ -- Stagwell Chairman and CEO Mark Penn released a statement today in response to the Supreme Court's decision to overturn Roe v. Wade.

"We are singularly focused on supporting our people through this transition. While we cannot predict how abortion access will evolve in the coming months, or even years, Stagwell believes employees should have access to excellent health care, regardless of their location. We are taking immediate steps that will expand our network travel benefits to give employees access to the nearest approved reproductive healthcare provider in a legally permissible way," said Penn. "We hope this travel benefit will provide employees located in states that have implemented new restrictions on reproductive rights with access to care."

About Stagwell

Stagwell is the challenger network built to transform marketing. We deliver scaled creative performance for the world's most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our 12,000+ specialists in 34+ countries are unified under a single purpose: to drive effectiveness and improve business results for their clients. Join us at www.stagwellglobal.com.

Contact

Beth Sidhu
[email protected]
202-423-4414 

Stagwell is the challenger network built to transform marketing. (PRNewsfoto/Stagwell Inc.)

 

SOURCE Stagwell Inc.


These press releases may also interest you

at 01:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...

at 00:16
WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA...

at 00:00
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101...

9 mai 2024
TCI Group is proud to be participating in Phase 1 of the Alliance for Water Stewardship (AWS) Impact Accelerator. Together we are working in Shanghai Jinshan with AWS Members and five other facilities to expand our knowledge, skills and networks to...

9 mai 2024
A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National...

9 mai 2024
Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be...



News published on and distributed by: